These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 18626278

  • 1. Neuroleptic malignant syndrome and the acute phase response.
    Rosebush PI, Anglin RE, Richards C, Mazurek MF.
    J Clin Psychopharmacol; 2008 Aug; 28(4):459-61. PubMed ID: 18626278
    [No Abstract] [Full Text] [Related]

  • 2. A malignant neuroleptic spectrum: review of diagnostic criteria and treatment implications in three case reports.
    Pandya M, Pozuelo L.
    Int J Psychiatry Med; 2004 Aug; 34(3):277-85. PubMed ID: 15666963
    [Abstract] [Full Text] [Related]

  • 3. [Neuroleptic malignant syndrome: a life-threatening complication that can be treated effectively].
    van Waarde JA, Muller ME, Verweg B.
    Ned Tijdschr Geneeskd; 2006 Nov 18; 150(46):2517-20. PubMed ID: 17152323
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Nifedipine use in neuroleptic malignant syndrome.
    Talley BJ, Taylor SE.
    Psychosomatics; 1994 Nov 18; 35(2):168-70. PubMed ID: 8171178
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neuroleptic rechallenge following neuroleptic malignant syndrome.
    Raju GV, Ramesh Kumar TC, Khanna S.
    Aust N Z J Psychiatry; 2000 Aug 18; 34(4):700. PubMed ID: 10954411
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The acute phase response and laboratory testing.
    Jupe D.
    Aust Fam Physician; 1996 Mar 18; 25(3):324-9. PubMed ID: 8867183
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Immobility in patients with advanced dementia may actually be a form of a Lorazepam-reversible catatonia].
    Alisky JM.
    Rev Med Chil; 2008 Oct 18; 136(10):1359-60. PubMed ID: 19194638
    [No Abstract] [Full Text] [Related]

  • 13. [Acute-phase reaction].
    Bonnotte B, Olsson NO, Lorcerie B.
    Rev Prat; 2003 Mar 01; 53(5):489-94. PubMed ID: 12722605
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Neuroleptic malignant syndrome: therapeutic difficulties].
    Pedrol E, Villalta J, Antúnez E, Grau JM.
    Med Clin (Barc); 1988 Oct 22; 91(13):516. PubMed ID: 3226206
    [No Abstract] [Full Text] [Related]

  • 16. Haloperidol-induced neuroleptic malignant syndrome complicated by hyperosmolar hyperglycemic state.
    Rock W, Elias M, Lev A, Saliba WR.
    Am J Emerg Med; 2009 Oct 22; 27(8):1018.e1-3. PubMed ID: 19857430
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Anesthetic management of a patient with mental disabilities as well as the past history of heat stroke and neuroleptic malignant syndrome].
    Takaishi K, Nakajo N.
    Masui; 2007 Sep 22; 56(9):1078-80. PubMed ID: 17877051
    [Abstract] [Full Text] [Related]

  • 19. Neuroleptic malignant syndrome induced by metoclopramide in an infant with Freeman-Sheldon syndrome.
    Stein MH, Sorscher M, Caroff SN.
    Anesth Analg; 2006 Sep 22; 103(3):786-7. PubMed ID: 16931708
    [No Abstract] [Full Text] [Related]

  • 20. Lorazepam reduces the serum brain-derived neurotrophic factor level in schizophrenia patients with catatonia.
    Huang TL, Hung YY.
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb 01; 33(1):158-9. PubMed ID: 19013208
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.